Viridian Therapeutics (VRDN) Competitors

RadNet (NASDAQ:RDNT) and Viridian Therapeutics (NASDAQ:VRDN) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability, media sentiment, community ranking and analyst recommendations.

Which has more volatility and risk, RDNT or VRDN?

RadNet has a beta of 1.46, suggesting that its share price is 46% more volatile than the S&P 500. Comparatively, Viridian Therapeutics has a beta of 0.57, suggesting that its share price is 43% less volatile than the S&P 500.

Do analysts recommend RDNT or VRDN?

RadNet currently has a consensus price target of $69.75, indicating a potential upside of 18.37%. Viridian Therapeutics has a consensus price target of $36.70, indicating a potential upside of 170.95%. Given Viridian Therapeutics' higher possible upside, analysts clearly believe Viridian Therapeutics is more favorable than RadNet.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RadNet	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	3.40
Viridian Therapeutics	0 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.91

Does the media prefer RDNT or VRDN?

In the previous week, Viridian Therapeutics had 4 more articles in the media than RadNet. MarketBeat recorded 15 mentions for Viridian Therapeutics and 11 mentions for RadNet. Viridian Therapeutics' average media sentiment score of 1.41 beat RadNet's score of 0.79 indicating that Viridian Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RadNet	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Viridian Therapeutics	14 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has better valuation & earnings, RDNT or VRDN?

RadNet has higher revenue and earnings than Viridian Therapeutics. RadNet is trading at a lower price-to-earnings ratio than Viridian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RadNet	$1.87B	2.37	$3.04M	-$0.43	-137.03
Viridian Therapeutics	$302K	3,659.48	-$237.73M	-$3.85	-3.52

Do institutionals & insiders have more ownership in RDNT or VRDN?

77.9% of RadNet shares are held by institutional investors. 5.1% of RadNet shares are held by insiders. Comparatively, 1.6% of Viridian Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Is RDNT or VRDN more profitable?

RadNet has a net margin of -0.25% compared to Viridian Therapeutics' net margin of -85,127.16%. RadNet's return on equity of 4.29% beat Viridian Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RadNet	-0.25%	4.29%	1.45%
Viridian Therapeutics	-85,127.16%	-70.12%	-41.49%

Does the MarketBeat Community prefer RDNT or VRDN?

RadNet received 276 more outperform votes than Viridian Therapeutics when rated by MarketBeat users. However, 80.00% of users gave Viridian Therapeutics an outperform vote while only 66.17% of users gave RadNet an outperform vote.

Company	Underperform	Outperform
RadNet	Outperform Votes 356 66.17%	Underperform Votes 182 33.83%
Viridian Therapeutics	Outperform Votes 80 80.00%	Underperform Votes 20 20.00%

Summary

RadNet beats Viridian Therapeutics on 12 of the 19 factors compared between the two stocks.